Mereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREO

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit for securities law violations due to misleading statements regarding its Phase 3 clinical trials, which did not meet their primary endpoints, leading to a significant drop in stock price [1]. Summary by Relevant Sections Allegations - The lawsuit alleges that Mereo BioPharma provided overly positive statements while concealing material adverse facts about the Phase 3 ORBIT and COSMIC programs, which failed to achieve their primary endpoints of reducing annualized clinical fracture rates compared to placebo or bisphosphonate control groups [1]. - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies achieved statistical significance, despite improvements in bone mineral density [1]. Stock Price Impact - Following the announcement of the failed clinical trials, Mereo's American Depositary Shares (ADS) price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [1]. Class Action Details - Shareholders who purchased Mereo shares during the class period from June 5, 2023, to December 26, 2025, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, with a deadline set for April 6, 2026 [1]. - Participation in the class action does not require appointment as lead plaintiff, and there is no cost or obligation for shareholders to register [1].